Research News for Chester County

Annovis Bio Reports Promising Biomarker Results Showing Anti-Inflammatory, Neuroprotective Effects of Buntanetap in Alzheimer’s Patients

October 13, 2025October 12, 2025 - by Timothy Alexander

MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) announced new clinical findings indicating that its lead candidate, buntanetap, reduces inflammation and improves cellular health in patients with Alzheimer’s disease, suggesting …

Research

Neuraptive Therapeutics Enrolls First Patient in Phase 3 Trial for NTX-001 Nerve Repair Therapy

October 11, 2025October 10, 2025 - by Timothy Alexander

CHESTERBROOK, PA — Neuraptive Therapeutics, Inc. announced the enrollment of the first patient in its phase 3 clinical trial evaluating NTX-001, an investigational therapy designed to improve outcomes in patients …

Research

Palvella Expands QTORIN Rapamycin Program Into Rare Angiokeratomas

September 29, 2025September 28, 2025 - by Timothy Alexander

WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) announced it will expand development of its investigational therapy QTORIN™ 3.9% rapamycin anhydrous gel into clinically significant angiokeratomas, a rare and debilitating …

Research

Annovis Bio Publishes Data on New Crystal Form of Lead Alzheimer’s Drug

September 28, 2025September 27, 2025 - by Timothy Alexander

MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) announced the publication of a peer-reviewed article in Biomolecules detailing the pharmacokinetic profile of a newly developed crystal form of buntanetap, its …

Research

Palvella Completes Phase 2 Trial of QTORIN Rapamycin for Cutaneous Venous Malformations

September 28, 2025September 27, 2025 - by Timothy Alexander

WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) announced it has completed TOIVA, a Phase 2 proof-of-concept trial of QTORIN™ 3.9% rapamycin anhydrous gel, for the treatment of cutaneous venous …

Research

Annovis Bio Publishes Data on New Crystal Form of Alzheimer’s Drug Candidate

September 20, 2025September 19, 2025 - by Timothy Alexander

MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) has published new research in the journal Biomolecules detailing the pharmacokinetic profile of a new crystal form of buntanetap, its lead drug …

Research

Palvella Completes Phase 2 Trial of QTORIN Rapamycin for Rare Skin Disorder

September 20, 2025September 19, 2025 - by Timothy Alexander

WAYNE, PA — Palvella Therapeutics, Inc. (Nasdaq: PVLA) has completed TOIVA, its Phase 2 clinical trial evaluating QTORIN™ 3.9% rapamycin anhydrous gel as a potential treatment for cutaneous venous malformations …

Research

Endo Highlights New Data on Potential Treatments for Painful Foot Disorders at Orthopaedic Conference

September 16, 2025September 15, 2025 - by Timothy Alexander

MALVERN, PA — Endo is presenting new clinical data on collagenase clostridium histolyticum (CCH) as a potential nonsurgical treatment for plantar fibromatosis (PFI) and plantar fasciitis (PFA) during the American …

Research

Teleflex Launches Clinical Trial Testing Dual-Device Heart Procedure for Diabetic Patients

September 14, 2025September 13, 2025 - by Timothy Alexander

WAYNE, PA — Teleflex Incorporated (NYSE: TFX) has announced the enrollment of the first patient in the DUBSTENT DIABETES trial, a new clinical study designed to evaluate whether combining two …

Research

Ocugen Gains EMA Backing for Single Pivotal Trial to Support Stargardt Disease Gene Therapy Approval

August 16, 2025August 14, 2025 - by Timothy Alexander

MALVERN, PA — Ocugen, Inc. (NASDAQ: OCGN) has received a key regulatory boost in its bid to bring a gene therapy for Stargardt disease to market, with the European Medicines …